Last update 27 Dec 2024
Aflibercept biosimilar (Mabwell Bioscience)
Last update 27 Dec 2024
Overview
Basic Info
Drug Type Biosimilar, Fusion protein |
Synonyms Aflibercept Biosimilar (Mabwell (Shanghai) Bioscience Co., Ltd.), 阿柏西普生物类似药（Mabwell (Shanghai) Bioscience Co., Ltd.）, 9MW-0813 + [1] |
Target |
Mechanism PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 4715606
The sequence is quoted from: *****
Related
4
Clinical Trials associated with Aflibercept biosimilar (Mabwell Bioscience)Phase III Clinical Study of the Efficacy and Safety of 9MW0813 and Aflibercept (EYLEA®) in Patients With Diabetic Macular Edema (DME) in a Multicenter, Randomized, Double-blind, Parallel Active-controlled Study
多中心、随机、双盲、平行阳性对照评价9MW0813和阿柏西普（EYLEA®）在糖尿病性黄斑水肿（DME）患者中的有效性和安全性III期临床研究
[Translation] A multicenter, randomized, double-blind, parallel positive-controlled Phase III clinical study to evaluate the efficacy and safety of 9MW0813 and aflibercept (EYLEA®) in patients with diabetic macular edema (DME)
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase I Trial Comparing the Safety, Pharmacokinetics and Efficacy of 9MW0813 and Aflibercept (EYLEA®) After a Single Dose in Patients With Diabetic Macular Edema (DME)
100 Clinical Results associated with Aflibercept biosimilar (Mabwell Bioscience)
Login to view more data
100 Translational Medicine associated with Aflibercept biosimilar (Mabwell Bioscience)
Login to view more data
100 Patents (Medical) associated with Aflibercept biosimilar (Mabwell Bioscience)
Login to view more data
100 Deals associated with Aflibercept biosimilar (Mabwell Bioscience)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetic macular oedema | Phase 3 | CN | 17 Feb 2022 | |
| Wet age-related macular degeneration | Phase 3 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free